

# Supplementary information for “Estimating antibiotic cross-resistance patterns in hospitalized patients through Bayesian network modelling”

Stacey S Cherny<sup>1,2</sup>, Daniel Nevo<sup>3</sup>, Avi Baraz<sup>1,2,3</sup>, Shoham Baruch<sup>1,2</sup>, Ohad Lewin-Epstein<sup>4</sup>,  
Gideon Y Stein<sup>5,6</sup>, Uri Obolski<sup>1,2,\*</sup>

<sup>1</sup>School of Public Health, Tel Aviv University, Tel Aviv, Israel

<sup>2</sup>Porter School of the Environment and Earth Sciences, Tel Aviv University, Tel Aviv, Israel

<sup>3</sup>Department of Statistics and Operations Research, Tel Aviv University, Tel Aviv, Israel

<sup>4</sup>Department of Molecular Biology and Ecology of Plants, Tel Aviv University, Tel Aviv, Israel

<sup>5</sup>Internal Medicine “A”, Meir Medical Center, Kfar Saba, Israel

<sup>6</sup>Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

\*to whom correspondence should be addressed: [uriobols@tauex.tau.ac.il](mailto:uriobols@tauex.tau.ac.il)

**Table S1: Antibiotic resistances excluded from analysis due to redundancies or missing data, along with their tetrachoric correlations with highly-correlated included variables**

<b>Dataset</b>	<b>Antibiotic removed</b>	<b>Antibiotic(s) it is correlated with</b>	<b>Tetrachoric correlation</b>
<i>E. coli</i>	Amikacin	Ampicillin	0.97
<i>E. coli</i>	Ceftazidime	Cefuroxime	1.00
<i>E. coli</i>	Ceftriaxone	Cefuroxime	1.00
<i>E. coli</i>	Cefuroxime	Ciprofloxacin	0.79
<i>E. coli</i>	Cefuroxime	Ofloxacin	1.00
<i>E. coli</i>	Ertapenem	Cefuroxime	0.94
<i>K. pneumoniae</i>	Ceftazidime	Cefuroxime	1.00
<i>K. pneumoniae</i>	Ceftriaxone	Cefuroxime	1.00
<i>K. pneumoniae</i>	Ertapenem	Cefuroxime	0.94
<i>K. pneumoniae</i>	Cefuroxime	Ciprofloxacin	0.82
<i>K. pneumoniae</i>	Sulf-Trim	Ciprofloxacin	0.78
<i>K. pneumoniae</i>	Sulf-Trim	Gentamicin	0.83
<i>P. aeruginosa</i>	Amikacin	Gentamicin	0.94
<i>P. aeruginosa</i>	Amikacin	Ofloxacin	0.79
<i>P. aeruginosa</i>	Pipera	Ceftazidime	0.95
<i>P. mirabilis</i>	Amikacin	Gentamicin	0.69
CoNS	Clindamycin	Erythromycin	0.95
CoNS	Clindamycin	Ofloxacin	0.84

Note: Sulf-Trim = sulfamethoxazole-trimethoprim

**Table S2: The maximum number of parents sufficient to reach the maximum likelihood seen, the number of arcs in this model, and the number of arcs present in at least 50% of the simulations, representing the final models presented, for each of the 5 bacteria analyzed.**

Bacteria	Max parents needed	Initial # of arcs	Arcs in 50% of simulations
<i>Escherichia coli</i>	4	23	21
<i>Klebsiella pneumoniae</i>	3	10	10
<i>Pseudomonas aeruginosa</i>	4	12	12
<i>Proteus mirabilis</i>	3	17	17
<i>Staphylococcus coag. neg. group</i>	4	26	18

Figure S1: Consistency matrix showing proportion of models which contain a given arc. Hospitalized = Log(Days Hospitalized + 1); AMK = amikacin; AMP = ampicillin; CAZ = ceftazidime; CXM = cefuroxime; CHL = chloramphenicol; CIP = ciprofloxacin; ERY = erythromycin; Fusid = fusidic acid; GEN = gentamicin; IPM = imipenem; OFX = ofloxacin; OXA = oxacillin; Sulf-Trim = sulfamethoxazole-trimethoprim. The sign and proportion of arcs is represented by color.

